Literature DB >> 24267364

Allergists' self-reported adherence to anaphylaxis practice parameters and perceived barriers to care: an American College of Allergy, Asthma, and Immunology member survey.

Stanley Fineman1, Paul Dowling, Dianne O'Rourke.   

Abstract

BACKGROUND: Anaphylaxis is life-threatening and requires rapid medical intervention. Knowledge of treatment guidelines and addressing barriers to care are essential for appropriate management.
OBJECTIVE: To investigate allergists' self-reported practices in managing patients at risk for anaphylaxis, specifically in following practice parameters for diagnosis, treatment, and appropriate use of epinephrine, and to identify perceived barriers to care.
METHODS: Online questionnaires were distributed to members of the American College of Allergy, Asthma, and Immunology. The US physicians who self-identified as "allergist/immunologist" were eligible to participate. The first 500 completed questionnaires were analyzed.
RESULTS: Nearly all (≥95%) reported adherence to practice parameters in prescribing an epinephrine auto-injector and instructing patients on its use, taking a detailed allergy history, counseling patients on avoidance measures, and educating patients on the signs and symptoms of anaphylaxis. More than 90% stated they determined the best diagnostic procedures to identify triggers and coordinated laboratory and allergy testing. Adherence to practice parameters was less robust for providing patients with written action plans and in-office anaphylaxis preparedness. Perceived barriers to care included a significant proportion of patients who were uncomfortable using epinephrine auto-injectors and inadequate knowledge of anaphylaxis among referral physicians.
CONCLUSION: Allergists overwhelmingly adhere to practice parameter recommendations for the treatment and management of anaphylaxis, including appropriate use of epinephrine as first-line treatment, educating patients, and testing to diagnose anaphylaxis and identify its triggers. Opportunities for improvement include preparing staff and patients for anaphylactic events, providing written action plans, and improving knowledge of referring physicians.
Copyright © 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24267364     DOI: 10.1016/j.anai.2013.09.026

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  5 in total

1.  How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients.

Authors:  Erminia Ridolo; Marcello Montagni; Laura Bonzano; Eleonora Savi; Silvia Peveri; Maria Teresa Costantino; Mariangiola Crivellaro; Giuseppina Manzotti; Carlo Lombardi; Marco Caminati; Cristoforo Incorvaia; Gianenrico Senna
Journal:  Intern Emerg Med       Date:  2015-05-20       Impact factor: 3.397

2.  Anaphylaxis in America: A national physician survey.

Authors:  Ashley M Altman; Carlos A Camargo; F Estelle R Simons; Philip Lieberman; Hugh A Sampson; Lawrence B Schwartz; F Myron Zitt; Charlotte Collins; Michael Tringale; Marilyn Wilkinson; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2015-01-07       Impact factor: 10.793

3.  International consensus on (ICON) anaphylaxis.

Authors:  F Estelle R Simons; Ledit Rf Ardusso; M Beatrice Bilò; Victoria Cardona; Motohiro Ebisawa; Yehia M El-Gamal; Phil Lieberman; Richard F Lockey; Antonella Muraro; Graham Roberts; Mario Sanchez-Borges; Aziz Sheikh; Lynette P Shek; Dana V Wallace; Margitta Worm
Journal:  World Allergy Organ J       Date:  2014-05-30       Impact factor: 4.084

Review 4.  Diagnosis and treatment of anaphylaxis: there is an urgent needs to implement the use of guidelines.

Authors:  Maria Luiza Kraft Köhler Ribeiro; Herberto José Chong Neto; Nelson Augusto Rosario Filho
Journal:  Einstein (Sao Paulo)       Date:  2017-12-07

5.  A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy.

Authors:  Vibha Sharma; Jennifer Jobrack; Wendy Cerenzia; Stephen Tilles; Robert Ryan; Regina Sih-Meynier; Stefan Zeitler; Michael Manning
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.